Anton Hagenbeek, MD, PhD, was a Professor of Hematology in the Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Prof. Hagenbeek obtained his medical degree from the Erasmus University, Rotterdam, The Netherlands, in 1972. While working towards his medical degree, Prof. Hagenbeek undertook research in experimental hematology at the Radiobiological Institute TNO, Rijswijk, The Netherlands, where he also later received his PhD in 1977. Prof. Hagenbeek then undertook his residency in internal medicine at the Erasmus University, Rotterdam, The Netherlands, followed by his fellowship in hematology at the University of California, Los Angeles, CA. In 1981, Prof. Hagenbeek received a Fulbright award and spent a year at the University of California, Los Angeles, CA, where he became involved in the clinical aspects of transplantation.
Prof. Hagenbeek was heavily involved in clinical trials for the Lunenburg Lymphoma Biomarker Consortium (LLBC)/ Lunenburg Lymphoma Phase I/II Consortium (LLPC). He was also on the advisory board of a number of hemato-oncology journals and congresses and had active involvement in communication meetings and press briefings at the EHA.
Prof. Hagenbeek sadly passed away in 2021 at the age of 73. He has undoubtedly given the field of hemato-oncology some incredibly valuable contributions.
Developmental therapeutics for hematological malignancies
Prof. Hagenbeek’s main research interests consisted of novel therapeutics for hematological malignancies. He was involved in clinical trials for relapsed/refractory classical Hodgkin lymphoma. One such clinical trial Prof. Hagenbeek led was the Phase II HOVON/LLPC Transplant BRaVE study (NCT02280993) investigating the combination of brentuximab vedotin with second line salvage chemotherapy.